Perseus Proteomics Inc. [4882.T]
TOKYO, May 20 (Pulse News Wire) – Perseus Proteomics Inc. (4882.T) held a briefing for analysts and institutional investors on May 18, 2026 to discuss its fiscal year ending March 2026.
During the session, the company addressed ongoing efforts to secure partnerships for its drug candidates, particularly focusing on PPMX-T003 and PPMX-T002. Regarding PPMX-T003, despite delays, the company continues to engage with potential partners, having identified several interested firms. It plans to expand clinical applications beyond polycythemia vera while maintaining focus on the current therapeutic area.
For PPMX-T002, the primary challenge was unstable supply of actinium-225, but recent global improvements suggest a positive outlook moving forward. In addition, the company outlined future development timelines for PPMX-T004, planning to initiate manufacturing processes from January 2027 to March 2028, followed by GLP toxicity testing preparations. Despite challenges, management remains committed to realizing partnership deals for these assets, emphasizing their unique mechanisms and potential synergies in treatment regimens.
🟢 Confidence: High AI-translated content.